Chronic Obstructive Pulmonary Disease Pipeline Appears Robust With 65+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's "Chronic Obstructive Pulmonary Disease Pipeline Insight 2025" report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Obstructive Pulmonary Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Obstructive Pulmonary Disease Treatment Landscape. Click here to read more @ Chronic Obstructive Pulmonary Disease Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report
• In April 2025, Hoffmann-La Roche announced a study to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
• In April 2025, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. announced a Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
• In April 2025, AstraZeneca organized a phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).
• DelveInsight's Chronic Obstructive Pulmonary Disease pipeline report depicts a robust space with 65+ active players working to develop 70+ pipeline therapies for Chronic Obstructive Pulmonary Disease treatment.
• The leading Chronic Obstructive Pulmonary Disease Companies such as Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.
• Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies such as QVA149, NVA237, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.

Discover groundbreaking developments in Chronic Obstructive Pulmonary Disease therapies! Gain in-depth knowledge of key Chronic Obstructive Pulmonary Disease clinical trials, emerging drugs, and market opportunities @ Chronic Obstructive Pulmonary Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Emerging Drugs Profile
• Benralizumab: AstraZeneca
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the FcγRIIIα receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treat COPD.

• Dupilumab: Sanofi
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

• Tezepelumab: Amgen
Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

• SNG001: Synairgen
SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

• GSK3923868: GlaxoSmithKline
GSK3923868, is a PI4kβ inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

The Chronic Obstructive Pulmonary Disease Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
• Chronic Obstructive Pulmonary Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market

Stay informed about the Chronic Obstructive Pulmonary Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Obstructive Pulmonary Disease Unmet Needs- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Companies
Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Transform your understanding of the Chronic Obstructive Pulmonary Disease Pipeline! See the latest progress in drug development and clinical research @ Chronic Obstructive Pulmonary Disease Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report
• Coverage- Global
• Chronic Obstructive Pulmonary Disease Companies- Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.
• Chronic Obstructive Pulmonary Disease Pipeline Therapies- QVA149, NVA237, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Respiratory Diseases Research-Access the Full Chronic Obstructive Pulmonary Disease Pipeline Analysis Today! @ Chronic Obstructive Pulmonary Disease Drugs and Companies- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Tezepelumab: Amgen
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. GSK3923868: GlaxoSmithKline
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Chronic Obstructive Pulmonary Disease- Unmet Needs
21. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
22. Appendix

List of Top Selling Market Research Reports in 2025

Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Avascular Necrosis Market- https://www.delveinsight.com/report-store/avascular-necrosis-market
Bacterial Pneumonia Market- https://www.delveinsight.com/report-store/bacterial-pneumonia-market
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Carbapenem-resistant Enterobacteriaceae Infection Market- https://www.delveinsight.com/report-store/carbapenem-resistant-enterobacteriaceae-infection-market
Central Retinal Vein Occlusion Market- https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Chagas Disease Market- https://www.delveinsight.com/report-store/chagas-disease-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Digestive System Fistula Market- https://www.delveinsight.com/report-store/digestive-system-fistula-market
Elastomeric Pump Market- https://www.delveinsight.com/report-store/elastomeric-pump-market
Embolotherapy Market- https://www.delveinsight.com/report-store/embolotherapy-market
Ewing Sarcoma Market- https://www.delveinsight.com/report-store/ewing-sarcoma-market
Familial Lipoprotein Lipase Deficiency Pipeline- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
Gastroparesis Market- https://www.delveinsight.com/report-store/gastroparesis-market
Graves Disease Market- https://www.delveinsight.com/report-store/graves-disease-market
Hdac Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitor-pipeline-insight
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Immune Checkpoints Activator Companies- https://www.delveinsight.com/report-store/immune-checkpoints-activators
Japan Healthcare Outlook- https://www.delveinsight.com/report-store/japan-healthcare-outlook-report
Meibomian Gland Dysfunction Market- https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-market
Moderate To Severe Plaque Psoriasis Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Neurodermatitis Market- https://www.delveinsight.com/report-store/neurodermatitis-market
Neurofibromatosis Type 2 Market- https://www.delveinsight.com/report-store/neurofibromatosis-type-2-market-insight
Nk Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Nocturia Market- https://www.delveinsight.com/report-store/nocturia-market
Non-muscle Invasive Bladder Cancer Market- https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
Nonalcoholic Steatohepatitis Market- https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
Opioid-related Disorders Market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
Palmar Fibromatosis Market- https://www.delveinsight.com/report-store/palmar-fibromatosis-market
Peanut Allergy Market- https://www.delveinsight.com/report-store/peanut-allergy-market
Pediatric Growth Hormone Deficiency Market- https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
Perennial Allergic Rhinitis Market- https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
Phototherapies For Psoriasis Market- https://www.delveinsight.com/report-store/phototherapy-devices-market
Pleural Effusion Market- https://www.delveinsight.com/report-store/pleural-effusion-market
Postpartum Depression Market- https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Primary Mediastinal Large B-cell Lymphoma Market- https://www.delveinsight.com/report-store/primary-mediastinal-large-b-cell-lymphoma-market
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
Relapsing Refractory Multiple Myeloma Market- https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-market
Restless Legs Syndrome Market- https://www.delveinsight.com/report-store/restless-leg-syndrome-market
Rosacea Market - https://www.delveinsight.com/report-store/rosacea-market
Scabies Market- https://www.delveinsight.com/report-store/scabies-market
Seasonal Allergic Rhinitis Market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
Surgical Bleeding Market- https://www.delveinsight.com/report-store/surgical-bleeding-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Systemic Inflammatory Response Syndrome Market- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Tay-sachs Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Tendinopathy Market- https://www.delveinsight.com/report-store/tendinopathy-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Trauma Fixation Devices Market- https://www.delveinsight.com/report-store/trauma-devices-market
Trichotillomania Market- https://www.delveinsight.com/report-store/trichotillomania-ttm-market
Uncomplicated Urinary Tract Infection Market- https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
Urinary Retention Market- https://www.delveinsight.com/report-store/urinary-retention-market
Urothelial Carcinoma Market- https://www.delveinsight.com/report-store/urothelial-carcinoma-market
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.